Clinical trial
Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced…
NCT00014261 · Dartmouth-Hitchcock Medical Center, Other · Completed
Key facts
| NCT number | NCT00014261 |
|---|---|
| Title | Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors |
| Official title | A Phase-I Study Of Cyclical Oral Administration Of Temozolomide In Combination With PEG12000-Interferon Alfa-2B In Patients With Refractory And/Or Advanced Solid Tumors |
| Lead sponsor | Dartmouth-Hitchcock Medical Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological, Drug |
| Interventions | PEG-interferon alfa-2b, temozolomide |
| Start date | Oct 1, 2000 |
| Primary completion | Nov 1, 2002 |
| Completion | Nov 1, 2002 |
| First posted | Jul 30, 2003 |
| Last update posted | Mar 30, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: